1-14 of 14
Michael Byrne
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Guillermo Garcia-Manero, Amanda Przespolewski, Yasmin Abaza, Michael Byrne, Abraham P. Fong, Feng Jin, Alison J. Forgie, Athanasios C. Tsiatis, Shanhong Guan, Harry P. Erba
Journal: Blood
Blood (2022) 140 (Supplement 1): 9046–9047.
https://doi.org/10.1182/blood-2022-157606
Published: 2022
Journal Articles

Insulin Secretion and β-Cell Function Are Preserved in Patients with Treated Hematological Malignancies

Rahul Shah, J. Matthew Luther, Michael Byrne, Dae Kwang Jung, Salyka M. Sengsayadeth, Bhagirathbhai Dholaria, Adetola A. Kassim, Bipin N. Savani, Wichai Chinratanalab, Reena Jayani, Brian G. Engelhardt
Journal: Blood
Blood (2022) 140 (Supplement 1): 6088–6089.
https://doi.org/10.1182/blood-2022-163409
Published: 2022
Journal Articles

TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Jennifer Marvin-Peek, Ashwin Kishtagari, Reena Jayani, Bhagirathbhai Dholaria, Tae Kon Kim, Emily F Mason, Brian G. Engelhardt, Heidi Chen, Adetola A. Kassim, Michael R. Savona, Bipin Savani, Michael Byrne
Journal: Blood
Blood (2022) 140 (Supplement 1): 11638–11640.
https://doi.org/10.1182/blood-2022-164631
Published: 2022
Journal Articles

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael Maris, Paolo Ghia, Michael Byrne, Nancy L. Bartlett, John M. Pagel, Yan Zheng, Justyna Kanska, Wangshu Zhang, Behzad Kharabi Masouleh, Enrique Granados, Javier Pinilla Ibarz
Journal: Blood
Blood (2022) 140 (Supplement 1): 7454–7456.
https://doi.org/10.1182/blood-2022-167868
Published: 2022
Journal Articles

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Clinical Trials & Observations
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani, John E. Godwin, Martha L. Arellano, Kendra L. Sweet, Ashkan Emadi, Farhad Ravandi, Harry P. Erba, Michael Byrne, Laura Michaelis, Max S. Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin A. Huls, Mojca Jongen-Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick J. Stiff, Kristen M. Pettit, Bob Löwenberg, Sarah E. Church, Erica Anderson, Jayakumar Vadakekolathu, Marianne Santaguida, Michael P. Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B. Walter, Jan K. Davidson-Moncada, Sergio Rutella, John F. DiPersio
Journal: Blood
Blood (2021) 137 (6): 751–762.
https://doi.org/10.1182/blood.2020007732
Published: 2021
Includes: Supplemental data
Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4055.
https://doi.org/10.1182/blood-2018-99-117257
Published: 2018
Journal Articles

Successful Salvage with Inotuzumab Ozogamicin in Relapsed/Refractory Lymphoid Blast Crisis of Chronic Myeloid Leukemia after Failure of Multiple Lines of Therapy Including Blinatumomab

Alay Mansurov, MD, Michael Byrne, MD, Koyamangalath Krishnan, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5452.
https://doi.org/10.1182/blood-2018-99-114170
Published: 2018
Journal Articles

Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia

Katie S Gatwood, PharmD, Kathryn A Culos, PharmD, Laura A Binari, MD, Brian G Engelhardt, MD, Adetola A. Kassim, MD MS, Michael Byrne, MD, Stacey A Goodman, MD MS, Wichai Chinratanalab, MD, Salyka M. Sengsayadeth, MD, John P. Greer, MD, Madan Jagasia, MD MBBS, MS, Bipin N. Savani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3210.
https://doi.org/10.1182/blood.V130.Suppl_1.3210.3210
Published: 2017
Journal Articles

Similar Outcomes of Early Failure Steroid Dependent Acute GvHD and Upfront Steroid Refractory Acute GvHD: Implications on Clinical Trials

Karina A Mendoza, BS, Heidi Chen, PhD, Brian G Engelhardt, MD, Bipin N. Savani, MD, Stacey A Goodman, MD MS, Jeremy Warner, MD MS, Adetola A. Kassim, MD MS, Michael Byrne, MD, Wichai Chinratanalab, MD, John P. Greer, MD, Carole Hunt, Madan Jagasia, MD MBBS, MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1975.
https://doi.org/10.1182/blood.V130.Suppl_1.1975.1975
Published: 2017
Journal Articles

A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies

Amer M. Zeidan, MD, Rachel J. Cook, MD, Rodolfo Bordoni, MD, Ekaterine Asatiani, MD, Gongfu Zhou, Théa Faivre, Michael Byrne, MD, Michael R. Savona, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 640.
https://doi.org/10.1182/blood.V130.Suppl_1.640.640
Published: 2017
Journal Articles

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

Michael Byrne, MD, William Donnellan, Manish R Patel, MD, Amer M. Zeidan, MD, Mohamad Cherry, MDMS, Maria R. Baer, MD, Amir T. Fathi, MD MD BS, Jason Kaplan, MD, Feng Zhou, Fred Zheng, MD, April M. Barbour, Michael R. Savona, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2585.
https://doi.org/10.1182/blood.V130.Suppl_1.2585.2585
Published: 2017
Journal Articles

PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice

Xiaodong Cheng, Michael Byrne, Kevin D. Brown, Marina Y. Konopleva, Steven M. Kornblau, Richard L. Bennett, W. Stratford May
Journal: Blood
Blood (2015) 126 (13): 1585–1594.
https://doi.org/10.1182/blood-2015-03-635227
Published: 2015
Includes: Supplemental data
Journal Articles

PKR regulates proliferation, differentiation, and survival of murine hematopoietic stem/progenitor cells

Xiangfei Liu, Richard L. Bennett, Xiaodong Cheng, Michael Byrne, Mary K. Reinhard, W. Stratford May, Jr
Journal: Blood
Blood (2013) 121 (17): 3364–3374.
https://doi.org/10.1182/blood-2012-09-456400
Published: 2013
Journal Articles

Interleukin-1 (IL-1) Inhibits Growth of Cytomegalovirus in Human Marrow Stromal Cells: Inhibition Is Reversed Upon Removal of IL-1

Mineo Iwata, Jeff Vieira, Michael Byrne, Heidi Horton, Beverly Torok-Storb
Journal: Blood
Blood (1999) 94 (2): 572–578.
https://doi.org/10.1182/blood.V94.2.572
Published: 1999